Form 4: Anixa Biosciences Director Acquires 2,000 Shares in Open Market Purchase

Anixa Biosciences director Lewis H. Titterton Jr. purchased 2,000 shares of common stock at $3.01 per share on January 22, 2025.

Summary

• On January 22, 2025, Lewis H. Titterton Jr., a director at Anixa Biosciences, acquired 2,000 shares of the company's common stock.
• The shares were purchased at a price of $3.01 each.
• Following this transaction, Mr. Titterton directly owns 930,334 shares of Anixa Biosciences common stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. A director buying shares is generally a good sign, but the transaction is small and not a major event.

Positives

• A director's purchase of shares can be seen as a positive signal of confidence in the company's future prospects.

Industry Context

Insider trading activity is closely monitored by investors as it can provide insights into management's view of the company's prospects. This purchase by a director is a common occurrence and is not unusual.

Comparison to Industry Standards

• Director share purchases are a common occurrence in publicly traded companies.
• The size of this purchase is relatively small compared to the overall shareholding of the director.
• Such transactions are often seen as a sign of confidence, but the impact on the share price is usually minimal unless the transaction is very large or part of a larger trend.

Stakeholder Impact

• The share purchase may have a minor positive impact on shareholder sentiment.

Key Dates

Keywords

Anixa Biosciences, insider trading, share purchase, director, common stock, Lewis H. Titterton Jr.